What DHEA Eljot Treats: Main Uses and Benefits

DHEA Eljot (Prasterone) is generally considered relevant for addressing specific, moderate to severe symptoms arising from vulvovaginal atrophy in postmenopausal women. Its use focuses on symptoms linked to organ-specific functional stress and chronic changes in tissue health. It is commonly used to help manage conditions that present with significant symptomatic burden, including Genitourinary Syndrome of Menopause (GSM).

The primary use is to assist with symptoms related to vaginal dryness, chronic irritation, and burning. The medication is particularly applied in situations where additional symptomatic support is needed to address moderate to severe dyspareunia (painful intercourse), which is a common and noticeable manifestation. This therapeutic approach helps address symptom clusters that interfere with daily comfort and may assist with maintaining functional stability.

“This therapy is relevant for easing symptoms and supports the management of functional stability in affected tissues.”

---

Quick Fact: Relief for Painful Intercourse

Area of Relief	Symptom Category	Benefit Frame
Dyspareunia	Sexual Pain/Discomfort	Contributes to improved comfort during periods of heightened symptoms
Vaginal Atrophy	Tissue Thinning/Fragility	Helps ease the overall symptom burden

Regulatory References

1. NIH DailyMed drug information

Who Can and Cannot Use DHEA Eljot?

Eligibility for DHEA Eljot (Prasterone) is strictly defined by regulatory authorities (such as the FDA and EMA) and is based on the intended patient population and specific health conditions.

---

Approved and Contraindicated Populations

Population Status	Condition or Group
Approved Use	Adult postmenopausal women for the treatment of vulvovaginal atrophy (VVA) or GSM.
Contraindicated	Women with undiagnosed abnormal genital bleeding.
Contraindicated	Patients with a known or suspected history of breast cancer or other estrogen-dependent malignant tumors.

---

Age and Physiological Restrictions

• Pediatric Use: The medicine is not indicated for children or adolescents, as safety and effectiveness have not been established in this age group.
• Pregnancy and Lactation: Use is contraindicated during pregnancy and not recommended while breastfeeding.

Use Limitations

• Severe Impairment: DHEA Eljot is not recommended for patients with severe hepatic or severe renal impairment due to the lack of dedicated study data. The safety of using this drug concurrently with systemic hormone therapy has also not been established.

Interactions with Other Medicines and Products

The official regulatory profile for DHEA Eljot (Prasterone vaginal insert) is limited due to the drug's local administration and minimal absorption into the bloodstream. Regulatory authorities define the known interaction risks based on the drug's activity as a precursor to androgens and estrogens, and the route of administration.

---

Official Interaction Cautions

Category	Regulatory Statement Summary
Hormonal Agents	The co-administration of DHEA Eljot with other hormonal treatments containing estrogens or androgens is generally avoided due to the potential for additive hormonal effects.
Other Vaginal Products	Regulatory-based guidance advises against using any other vaginal products without consulting a healthcare professional, as this may alter the intended local action or absorption.
Metabolic Interactions	Drug interaction studies were not performed to evaluate the systemic effects of Prasterone on drug-metabolizing enzymes (e.g., CYP systems) or drug transporters.

---

Restrictions and Study Limitations

• Timing Requirements: No mandatory time separation windows (e.g., administer X hours apart) are specified in official prescribing information for Prasterone.
• Food and Supplements: No known interactions between the locally administered drug and food, alcohol, or herbal products are documented in regulatory sources.
• Specific Populations: The effects of hepatic or renal impairment on the drug’s potential for systemic interaction have not been studied by the manufacturer.

This limited structure reflects the drug’s design for targeted local use.

How DHEA Eljot Works: Mechanism of Action

Dehydroepiandrosterone (DHEA) employs a tripartite mechanism of action, primarily functioning as a pro-hormone. It serves as a precursor for specialized steroid-converting enzymes in peripheral tissues to synthesize active androgens and estrogens locally, a process termed intracrinology. This conversion modulates sex hormone signaling at the cellular level, resulting in localized changes in genomic and non-genomic receptor activation within tissues, including bone and skin.

Independently, DHEA acts as a neurosteroid in the brain, directly influencing neuronal excitability. It interacts with key receptor systems like GABA-A and NMDA, modulating central nervous system signaling. This adjusts the ratio of inhibitory to excitatory signaling, altering overall neuronal firing patterns.

Furthermore, DHEA engages in non-hormonal, regulatory activity by influencing key metabolic enzymes, such as Glucose-6-Phosphate Dehydrogenase ( G6PDH). This interaction affects pathways that regulate the flux of glucose and lipids. The mechanism influences the synthesis or activity of inflammatory mediators, affecting cellular responses.

How to Use DHEA Eljot: Official Administration Guidelines

DHEA Eljot (Prasterone) is administered according to a specific, standardized protocol, ensuring consistent local delivery of the fixed dose. The use of the medication is restricted to the intravaginal route only, utilizing a fixed dosage regimen.

Administration Scope (Core Facts)

Feature	Official Instruction
Route of administration	Intravaginal route only.
Dosing schedule	6.5 mg administered as one vaginal insert.
Timing	Administered once daily and specifically at bedtime.
Age-group rules	No dose adjustment is specified for older adults.
Course duration	Continued treatment requires reassessment at least every 6 months.

---

Resulting Procedural Structure and Missed Dose Rules

Official prescribing information provides clear instructions for proper insertion and the handling of timing errors.

• The medication must be inserted using the provided disposable applicator.
• The applicator should be pushed into the vagina as far as it can comfortably go without force.
• If a dose is forgotten, it must be skipped if the next dose is due in less than 8 hours.
• Doses must not be doubled to compensate for a missed one.

---

Connection to the Overall Use Protocol

This established protocol defines a precise, localized daily delivery method. The combination of the fixed 6.5 mg dose and the specific bedtime timing ensures adherence to the labeled frequency and procedure. These stringent instructions are designed to maintain a consistent use pattern and require mandatory, periodic professional review of the continued administration plan.

Research evidence / Overview of studies for DHEA Eljot

The clinical research for DHEA Eljot (Prasterone) was evaluated in studies concerning conditions associated with the decline of hormones after menopause. The evidence base relies primarily on data collected during short-term, controlled clinical trials (Randomized Controlled Trials or RCTs) and subsequent longer-term observation studies. The research aims to evaluate how symptoms and functional health markers change over time during the time participants were involved in the research.

---

Evidence for Symptoms of Vulvovaginal Atrophy / GSM

The medication was evaluated in research exploring conditions characterized by symptoms of Genitourinary Syndrome of Menopause (GSM), specifically dyspareunia (painful intercourse) and vaginal dryness. This research was conducted using short-term, placebo-controlled RCTs where the medication was compared against an inactive insert. These studies monitored patient-reported outcomes describing perceived discomfort.

Findings from Controlled Trials

In pivotal research, findings describe patterns observed in the studies over the 12-week primary evaluation period. The data show patterns related to changes measured in symptom scores (dyspareunia and vaginal dryness) and shifts measured in objective markers, such as Vaginal pH (tissue acidity) and changes in the Vaginal cell maturation index (measurement of cell composition). The evidence level for these primary findings is generally described as High.

Long-Term Research and Uncertainty

While primary controlled findings were limited to 12 weeks, extended research has explored longer-term use, with some open-label studies observing patterns over a 52-week duration. These longer studies were used to monitor the patterns of the initial reported measurements. However, the available information for long-term outcomes are not fully established, and the durability of the patterns measured beyond one year remains uncertain.

Limitations and Gaps

Comparative evidence is lacking regarding how Prasterone performs directly against other established local therapies for VVA/GSM symptoms. The research focused on women reporting moderate to severe symptoms. Data for certain groups, such as those with specific co-existing health conditions or various levels of symptom severity, remain insufficient. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Common questions about DHEA Eljot (FAQ)

---

Q: Is hair loss a reported side effect of DHEA Eljot?

Clinical trial data sometimes report unwanted hair loss, known medically as alopecia, as a self-reported event. However, the specific frequency or likelihood of this side effect is not consistently noted across all core regulatory documents. It is appropriate to discuss any concerns about hair changes with a healthcare provider.

---

Q: Do mood changes sometimes happen when using DHEA Eljot?

Regulatory documents for the vaginal insert do not list mood changes as a common or uncommon side effect. The drug’s active ingredient, Prasterone, does act as a neurosteroid, meaning it can influence central nervous system signaling. As a hormonal agent, broader information suggests the possibility of psychological symptoms, but these are not defined as typical adverse reactions.

---

Q: Does DHEA Eljot interact with common pain relievers like ibuprofen?

Official drug interaction studies with common non-hormonal medicines, such as ibuprofen, were not performed for the vaginal insert. This is generally due to the drug's design for local administration and minimal absorption into the bloodstream. Official guidance emphasizes the need to disclose all medicines to a healthcare provider.

---

Q: Can DHEA Eljot affect my liver test results?

Official information states the medicine is contraindicated (should not be used) in patients with acute liver disease. Its use is also not recommended for patients with severe hepatic impairment because dedicated study data is lacking. These restrictions indicate that the liver's function is a key safety consideration during treatment.

---

Q: Is it possible to have an allergic reaction to DHEA Eljot?

Yes, as with nearly all medicines, it is possible to experience an allergic reaction or hypersensitivity. Official safety information notes that unusual signs, such as a rash, itching, or swelling, should be reported to a healthcare provider immediately.

---

Q: Can DHEA Eljot cause weight gain or weight loss?

Official product information for the DHEA Eljot vaginal insert does not consistently list significant weight change as a common side effect. However, because the medicine is a prohormone and a steroid, broader information on the class of drugs sometimes reports weight gain as a potential effect due to its influence on metabolic and anabolic processes.

---

Q: Is it normal to feel nausea when first starting DHEA Eljot?

Nausea is not listed as a common or uncommon side effect in the core regulatory documents for the Prasterone vaginal insert. While nausea is sometimes associated with low levels of endogenous DHEA, it is not an expected adverse reaction when starting this specific medication.

---

Q: Does DHEA Eljot affect blood pressure?

Changes in blood pressure are not listed as a common or uncommon adverse effect in the official product information for DHEA Eljot. However, because the medicine is a hormonal agent, regulatory bodies advise close surveillance, as hormone levels can relate to blood pressure.

---

Q: Is DHEA Eljot used to treat fatigue?

No. According to the official regulatory documents, the medicine is only indicated (approved) for treating specific symptoms associated with vulvovaginal atrophy (VVA), such as painful intercourse (dyspareunia), in postmenopausal women. It is not approved for the treatment of general fatigue.

---

Q: Do studies show DHEA Eljot improving fertility?

No. The official documents state that the medicine is approved only for use in postmenopausal women. Furthermore, its use is contraindicated (should not be used) during pregnancy. This means DHEA Eljot is neither indicated nor studied for the purpose of improving fertility.

---

Q: Can DHEA Eljot interfere with blood thinning medication?

Specific interaction studies with blood thinners (anticoagulants) were not performed for the vaginal insert. While DHEA may interact with certain blood thinners like warfarin, potentially reducing their effect, the local administration limits systemic interaction. Healthcare providers should be consulted regarding all co-administered medicines.

---

Q: Is DHEA Eljot safe to use for people with diabetes?

Official labeling does not list diabetes as a contraindication for use. However, the medicine is known to influence metabolic pathways that regulate glucose and lipids. Due to potential metabolic effects, individuals with diabetes are typically advised to consult with their healthcare provider regarding use and monitoring.

---

Q: Does DHEA Eljot affect cholesterol levels?

The drug influences metabolic pathways that regulate the flux of lipids, which includes cholesterol. While the official product label does not list common effects on cholesterol, DHEA has been shown to potentially affect the lipoprotein profile in certain studies.

---

Q: Is DHEA Eljot described as a 'cure' for any condition?

No. The official regulatory documents and terminology do not describe DHEA Eljot as a cure for any condition. It is indicated for the treatment of specific symptoms associated with vulvovaginal atrophy and is intended to address these symptoms rather than providing a permanent cure.

How to Store and Dispose of DHEA Eljot?

Official Storage Requirements

To ensure product stability, the medicine must be stored according to the requirements defined in the official labeling:

• Temperature Constraint: Store this medicine below 25 C (room temperature).
• Environmental Protection: Keep the medicine in its original package and ensure the container is tightly closed to protect the contents from light and moisture.
• Child Safety: Always store DHEA Eljot out of the sight and reach of children.

Disposal Instructions

Proper disposal is essential to protect the environment. Never dispose of DHEA Eljot by flushing it down a toilet or mixing it with household waste. If the medicine is no longer needed or has expired, you must consult a pharmacist for specific instructions on how to dispose of the product responsibly, typically through a local take-back program.